Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol as Imatinib Synergiser in Unresectable or Metastatic GIST
2018-001295-37Phase 2Terminated
- Sponsor
- Erasmus Hospital
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cilostazol and imatinib in gastrointestinal stromal tumor (GIST), sponsored by Erasmus Hospital. Primary endpoint: Metabolic response on 18F-FDG PET. Started Aug 2018; status: terminated.
02
Drugs
cilostazolimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2018-001295-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001295-37.